Advertisement

Alkermes Inc. (Nasdaq: ALKS) has received a positive opinion from a key European regulatory committee for its experimental diabetes treatment, Bydureon. The recommendation means the drug candidate is very likely to be approved there.

The news is a boost for Waltham-based Alkermes, along with its partners, Indianapolis-based Eli Lilly and Company (NYSE: LLY), and San Diego, Calif.-based Amylin Pharmaceuticals Inc. (Nasdaq: AMLN), following a rejection from the U.S. Food and Drug Administration for the potential drug late last year.

SOURCE

Advertisement
Advertisement